Taiwan launches ARPA‑H‑funded kidney cell research as dialysis patients surge

The National Taiwan University Hospital has begun a three‑year autologous kidney‑cell expansion project that received funding from the U.S. Advanced Research Projects Agency for Health (ARPA‑H). In collaboration with the University of Chicago Medicine and other U.S. partners, researchers aim to harvest a few cells from a patient’s own kidney tissue, expand them ex vivo and later re‑implant them to slow chronic kidney disease progression. Taiwan faces a growing kidney‑failure burden, with close to 100,000 people on dialysis, only about 300 transplants performed annually and more than 8,000 patients awaiting a donor organ.

In parallel, a 25‑year‑old engineer in Taiwan was recently diagnosed with stage‑3 chronic kidney disease after ignoring persistent fatigue, eye‑lid swelling and foamy urine. Dr Hong Yong‑xiang warned that early kidney disease often lacks pain and that fatigue combined with edema, proteinuria and high blood pressure should prompt immediate medical evaluation. The case underscores the need for public awareness and early screening as the nation’s dialysis population continues to rise.